Viking Jumps 29.66% as Alibaba Fades From Its Chip-Day High
Three very different catalysts — an obesity trial readout, a sportswear growth target and a Chinese AI chip launch — produced three very different tapes on Sept. 22.
Viking Therapeutics (VKTX) rose 29.66% to 39.04 on Sept. 22, 2026 after its VK2735-102 maintenance study showed the obesity drug held up to 97% of weight loss versus 61% for placebo on every-other-week dosing, while ON Holding (ONON) gained 11.38% on high-teens sales growth guidance and Alibaba (BABA) added 0.62% after unveiling what it calls China's most powerful AI chip.
Three separate catalysts landed on the same session Tuesday, and the market graded them on a sharp curve. A maintenance-dosing readout from Viking Therapeutics (VKTX) drew the biggest reward. A multi-year sales target from ON Holding (ONON) drew the second. And Alibaba's (BABA) claim to have built China's most powerful AI chip drew the least — despite being, on paper, the most strategically consequential of the three.
As of 16:11 GMT on Sept. 22, Viking traded at 39.04, up 29.66% from a prior close of 30.11, inside a day range of 34.44 to 41.14. ON Holding was at 30.43, up 11.38% from 27.32, with a range of 28.93 to 31.16. Alibaba sat at 116.47, up 0.62% from 115.75 — but at the very bottom of a day range that reached 120.40.
Viking's readout attacks the part of obesity drugs patients actually quit over
The VK2735-102 maintenance study tested what happens when patients who have already lost weight move to every-other-week dosing. Viking reported the drug maintained up to 97% of weight loss, against 61% for placebo — a gap of 36 percentage points on the measure that matters most for a chronic therapy. Leerink analysts described the data as "stellar" and said it strengthens the drug's competitive profile, according to Bloomberg Markets.
Why the near-30% move? Because the commercial problem in obesity medicine has shifted. Efficacy on initial weight loss is now table stakes; the open questions are tolerability, persistence and what happens when a patient steps down. A maintenance regimen that holds nearly all the loss at half the dosing frequency speaks directly to cost, convenience and adherence — the three reasons real-world discontinuation rates run so far above trial rates. That is a differentiation argument against the entrenched incumbents rather than a me-too one.
The caution worth stating plainly: this is a single study readout on a drug still described as experimental, and the 97% figure is an upper bound, not an average patient outcome. A one-day repricing of this size embeds a lot of optimism about what a Phase 3 program and a regulatory file eventually look like. The stock's own intraday range — 34.44 to 41.14 — shows how wide the disagreement was even among buyers.
ON Holding sells a growth rate, not a quarter
ON Holding's gain came from guidance rather than results. The company signaled it expects sales growth in the high teens over the next several years, and framed the path around pushing into new sports — golf and football among them.
That is a specific kind of promise. Running-first brands historically hit a ceiling defined by the size of the running category; the way past it is category extension, which is expensive, slow, and frequently unrewarded. Football in particular is a boot-and-sponsorship business where shelf space is contested by entrenched global brands with decades of athlete relationships. Golf is a softer entry — apparel and footwear margins are attractive and the customer skews affluent — but it is also crowded.
The market's 11.38% response says investors are willing to underwrite the ambition rather than wait for evidence. What should be watched from here is whether the high-teens figure is repeated with the same confidence at the next reporting date, and whether the new categories show up as disclosed revenue lines rather than marketing narrative. Guidance stretching "over the next few years" is, by construction, not falsifiable for several quarters.
Alibaba's chip news gets a shrug from the tape
Alibaba unveiled what it calls China's most powerful AI chip and said it will expand data center capacity in the coming years. On strategic significance that is the heaviest item of the day: a domestic accelerator plus owned compute is the combination that would let Chinese cloud buyers reduce dependence on imported silicon.
38% response says investors are willing to underwrite the ambition rather than wait for evidence.
The price action was far more restrained. Alibaba opened the reaction strong enough to trade as high as 120.40 but was quoted at 116.47 — a fade of roughly 3.3% from the day's high, leaving it just 0.62% above the prior close. Three readings are plausible and not mutually exclusive: the announcement was partly anticipated; "most powerful in China" is a claim about a domestic field rather than a global benchmark, and investors want third-party silicon performance data before paying for it; and a stated plan to expand data center capacity is a capital spending commitment before it is a revenue line. Heavy compute build-outs compress free cash flow first and pay later.
A split tape underneath the three moves
The broader session offered little lift. The S&P 500 tracker (SPY) was at $773.25, down 0.03% from $773.50. The Dow 30 tracker (DIA) was weaker at $517.14, off 0.51%. Only the Nasdaq 100 tracker (QQQ) was meaningfully higher, at $745.03, up 0.48% from $741.47 — a familiar pattern in which technology carries the index while the cyclical-heavy average lags.
Against that flat-to-mixed backdrop, all three of Tuesday's movers were idiosyncratic: none needed help from the market, and the market did not provide any. That is worth noting for anyone assessing durability. Moves driven entirely by company-specific news are the ones most exposed to a second look — a competing dataset, a rival's launch, a clarification on spending. The near-term checkpoints are straightforward: whether Viking's maintenance data survives scrutiny from analysts outside Leerink, whether ON Holding's high-teens language is restated at its next results, and whether Alibaba quantifies the capital cost of the data center expansion it has now committed to.
Frequently asked questions
Why did Viking Therapeutics stock surge on Sept. 22, 2026?
Viking released data from its VK2735-102 maintenance study showing its experimental obesity drug VK2735 maintained up to 97% of weight loss, compared with 61% for placebo, when subjects switched to every-other-week dosing. Leerink analysts called the data stellar and said it strengthens the drug's competitive profile. Shares traded at 39.04, up 29.66% on the day.
What is a maintenance study and why does it matter for obesity drugs?
A maintenance study tests whether patients who have already lost weight keep that loss when the treatment regimen changes — here, moving to dosing every other week instead of weekly. It matters because real-world patients frequently stop obesity therapy over cost, convenience or tolerability. A regimen that preserves results at lower dosing frequency addresses adherence directly.
Why did ON Holding shares rise?
ON Holding said it expects sales growth in the high teens over the next few years as it expands beyond running into other sports, including golf and football. The market treated that multi-year growth framing as credible, sending shares to 30.43, up 11.38% from a prior close of 27.32, with an intraday range of 28.93 to 31.16.
Why was Alibaba's gain so small if the chip news was significant?
Alibaba unveiled what it calls China's most powerful AI chip and plans to expand data center capacity, but the stock closed the gap on its early advance. It was quoted at 116.47, only 0.62% above the prior close of 115.75, after trading as high as 120.40. Investors appear to want performance evidence and spending detail first.
How did the broader market trade that day?
The tape was mixed. The S&P 500 tracker SPY was at $773.25, down 0.03%. The Dow 30 tracker DIA fell 0.51% to $517.14. The Nasdaq 100 tracker QQQ rose 0.48% to $745.03. All three of the day's notable single-stock moves were driven by company-specific news rather than index direction.
What should investors watch next in these three stories?
For Viking, whether the maintenance data holds up under review beyond Leerink and what the next development stage looks like. For ON Holding, whether the high-teens growth target is repeated at the next results and whether golf and football show up as disclosed revenue. For Alibaba, the capital cost attached to its data center expansion.
Sources
- Alibaba Higher on Chip News; On Holdings Football Move | Stock Movers — Bloomberg Markets
